Targovax ASA: Notice of Annual General Meeting
15 mars 2018 02h01 HE
|
Targovax ASA
The Annual General Meeting of Targovax ASA will be held at the Company's offices at Lysaker, on 11 April 2018 at 10:00 CET. Please find the notice including agenda for the General Meeting and...
Targovax ASA: Issuance of restricted stock unites (RSUs) to the chairman of the board of directors
01 mars 2018 01h00 HE
|
Targovax ASA
Reference is made to the extraordinary general meeting of Targovax ASA (the "Company") on 30 November 2017, where Patrick Vink was elected as chairman of the Company's board of directors and the...
Targovax to present at Biologics World Nordic 2018
27 févr. 2018 01h01 HE
|
Targovax ASA
Oslo, Norway, 27 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that the Company will present at...
Targovax ASA: Fourth quarter and full year 2017 results
15 févr. 2018 01h01 HE
|
Targovax ASA
Oslo, Norway, 15 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its third quarter 2017...
Targovax announces completion of safety lead-in and preliminary immune activation data in ONCOS-102 trial in mesothelioma
07 févr. 2018 01h01 HE
|
Targovax ASA
Oslo, Norway, 7 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces completion of the safety...
Targovax ASA: Invitation to fourth quarter and full year 2017 results presentation Thursday 15 February
06 févr. 2018 01h01 HE
|
Targovax ASA
Oslo, Norway, 6 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its fourth quarter 2018...
Targovax ASA: Exercise price of options
02 févr. 2018 00h45 HE
|
Targovax ASA
With reference to the Stock exchange notification issued 1 February 2018 regarding options to employees: The exercise price of the granted options is NOK 17.17. The exercise price is equal to the...
Targovax ASA issues options to employees
01 févr. 2018 05h40 HE
|
Targovax ASA
On the basis of the approval by the Annual General Meeting on 5 April 2017 to authorize the Board of Targovax ASA to issue new shares to employees under the Company long-term incentive program, the...
Targovax announces the appointment of Michael Bogenstaetter as Chief Business Officer
08 janv. 2018 01h01 HE
|
Targovax ASA
Oslo, Norway, 8 January 2018: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that...
Targovax announces that ONCOS-102 generates immune activation in checkpoint inhibitor refractory melanoma patients
04 janv. 2018 01h01 HE
|
Targovax ASA
Oslo, Norway, 4 January 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces immune activation data in the...